UBS: Buy Biogen For Pipeline, M&A Potential

Some on the Street consider Biogen Inc BIIB’s bull thesis to be largely played out. But one analyst sees room for 15-percent upside. 

The Rating

UBS analyst Carter Gould upgraded Biogen to Buy and raised their price target from $318 to $410.

The Thesis

Biogen’s existing pipeline and potential asset acquisitions through 2018 present a $45-a-share opportunity, Gould said in a Wednesday note. 

Stabilization of the biotech’s multiple sclerosis business, clarity on negative Spinraza growth and 2019 data on the aducanumab Alzheimer’s trial affirm the “core pillars” of Biogen valuation and earnings per share estimates and positively skew the risk-reward, the analyst said.

“The current share price still implies minimal (if any) value for these assets,” the analyst said. “While these are high-risk programs, they (1) all have blockbuster potential, and (2) are not in Street models — implying success for any one likely drives upside from here.”

The pipeline compounds “increasing likelihood” that Biogen buys new assets with its $37-billion in capital, Gould said. 

The analyst said he expects a 2018 focus on the midstage neurology portfolio with trial results for stroke, neuropathic pain, Parkinson’s disease and amyotrophic lateral sclerosis. The indications are presently excluded from Street models and together represent a sales opportunity between $9 billion and $17 billion, according to UBS. 

Price Action

At the time of publication, shares were set to open up 1.4 percent at $357.55.

Related Links:

Here's Why Forward Pharma Lost 30% Today

BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A

Posted In: alzheimer's treatmentCarter Gouldmultiple sclerosisSpinrazaUBSAnalyst ColorBiotechUpgradesPrice TargetAnalyst RatingsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.